Bijoy Telivala (@BijoyTelivala) ranks #50 among US lung cancer KOLs, #28 among US breast cancer KOLs on X in 2026, by engagement from fellow physicians. 4 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: NATALEE, VOLGA, MAVERICK (SWOG S1827). CMS Open Payments lists $517 in 2025 general payments.
At a Glance
- 4 posts naming a trial in 2026
- 4 trials discussed by name
- Lung Cancer: US #50 · 3 physicians engaged
- Breast Cancer: US #28 · 4 physicians engaged
- CMS Open Payments lists $517 in 2025 general payments.
This Month
What Bijoy Telivala has posted in the last 30 days. Updated November 10, 2026.
We as the oncology community need to think hard if the 2 % OS benefit in Natalee is worth the financial cost esp outside US Herizon data looks great and should be SOC https://t.co/gdQI5jMQmn
Next meeting to watch: SABCS 2026 · San Antonio · Dec 8–11, 2026
Who Amplifies Bijoy Telivala
Physicians who reposted Bijoy Telivala’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #50 | — | 3 | 5 | Full ranking |
| Breast Cancer | #28 | — | 4 | 8 | Full ranking |
Trials Bijoy Telivala Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| NATALEE | 1 | #26 of 46 | Oct 23, 2026 |
| VOLGA | 1 | #30 of 57 | Sep 25, 2026 |
| MAVERICK (SWOG S1827) | 1 | #33 of 33 | Sep 13, 2026 |
| DESTINY-Breast11 | 1 | #11 of 11 | May 15, 2026 |
Bijoy Telivala on NATALEE
We as the oncology community need to think hard if the 2 % OS benefit in Natalee is worth the financial cost esp outside US Herizon data looks great and should be SOC https://t.co/gdQI5jMQmn
Bijoy Telivala on VOLGA
Volga vs EV 303 in bladder cancer Good to see trials reducing EV exposure Both for Cisplatin ineligible If both of their HR etc look same Will people be ok not using post op EV ? Interesting time for Bladder ca @RenoHemonc - using your pic @OncBrothers @SuyogCancer https://t.co/SRxqXStcfu
Bijoy Telivala on MAVERICK (SWOG S1827)
Glad this trial was done Data is compelling PCI was such a toxic things patients suffered for decades In this modern era , I am glad that we will not offer it to our patients any more https://t.co/9uGv5ZEEx7 [QUOTED] Landmark, practice changing study at #WCLC26. The phase III MAVERICK study shows no improvement in OS with PCI for SCLC, across limited and extensive stages, with worse cognitive failure free survival and increased toxicity in PCI arm. The end of the PCI era. https://t.co/SWOPM7iKux
Bijoy Telivala on DESTINY-Breast11
@OncBrothers @PTarantinoMD @SPremji7866 @DrSGraff Suspect yes Suspect T DXd followed by THP will the chosen regimen based on Destiny - Breast 11
Bijoy Telivala’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Great news !!!! Happy to see this happen Now be ready for the PBM shenanigans Drug can't be dispensed in local pharmacy Only Onco 360 and Biologics No idea why the drug manufacturer went that route https://t.co/pUOuXtxrme
Great study Many times more is not better and is actually harmful for patients https://t.co/HDPQwOVrFd
If this data can be replicated in non China 🇨🇳 studies this drug will replace a lot of I/O Here in Biliary tract and also King Keytruda in lung https://t.co/vYXDmbG5lJ
Great data set For any fit pt Ipi + NiVo should be SOC Problem happens in borderline pt Ipi has had such a bad name because BMS for years used 3 mg/kg and even 10mg /kg doses and patients had such horrendous toxicity https://t.co/uGBhw1gWRy
Revolutionary New Drug in Pancreatic Cancer Treatment Could Double Survival Rate Had a great time talking today about daraxonrasib and how the field of oncology is moving towards precision and targeted therapy https://t.co/Fqtk9QvhcO
Industry Payments
CMS Open Payments · 2025 general payments
$517 across 18 payments